Advertisement
ResearchIn-Press PreviewCell biologyOncology
Open Access | 10.1172/JCI183531
1Cancer Institute, Fudan University, Shanghai, China
2Department of Breast Surgery, Fudan University, Shanghai, China
3Institutes of Biomedical Sciences, Fudan University, Shanghai, China
4Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
Find articles by Yang, S. in: JCI | PubMed | Google Scholar
1Cancer Institute, Fudan University, Shanghai, China
2Department of Breast Surgery, Fudan University, Shanghai, China
3Institutes of Biomedical Sciences, Fudan University, Shanghai, China
4Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
Find articles by Jin, M. in: JCI | PubMed | Google Scholar
1Cancer Institute, Fudan University, Shanghai, China
2Department of Breast Surgery, Fudan University, Shanghai, China
3Institutes of Biomedical Sciences, Fudan University, Shanghai, China
4Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
Find articles by Andriani, L. in: JCI | PubMed | Google Scholar
1Cancer Institute, Fudan University, Shanghai, China
2Department of Breast Surgery, Fudan University, Shanghai, China
3Institutes of Biomedical Sciences, Fudan University, Shanghai, China
4Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
Find articles by Zhao, Q. in: JCI | PubMed | Google Scholar
1Cancer Institute, Fudan University, Shanghai, China
2Department of Breast Surgery, Fudan University, Shanghai, China
3Institutes of Biomedical Sciences, Fudan University, Shanghai, China
4Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
Find articles by Ling, Y. in: JCI | PubMed | Google Scholar
1Cancer Institute, Fudan University, Shanghai, China
2Department of Breast Surgery, Fudan University, Shanghai, China
3Institutes of Biomedical Sciences, Fudan University, Shanghai, China
4Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
Find articles by Lin, C. in: JCI | PubMed | Google Scholar
1Cancer Institute, Fudan University, Shanghai, China
2Department of Breast Surgery, Fudan University, Shanghai, China
3Institutes of Biomedical Sciences, Fudan University, Shanghai, China
4Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
Find articles by Huang, M. in: JCI | PubMed | Google Scholar
1Cancer Institute, Fudan University, Shanghai, China
2Department of Breast Surgery, Fudan University, Shanghai, China
3Institutes of Biomedical Sciences, Fudan University, Shanghai, China
4Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
Find articles by Cai, J. in: JCI | PubMed | Google Scholar
1Cancer Institute, Fudan University, Shanghai, China
2Department of Breast Surgery, Fudan University, Shanghai, China
3Institutes of Biomedical Sciences, Fudan University, Shanghai, China
4Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
Find articles by Zhang, Y. in: JCI | PubMed | Google Scholar
1Cancer Institute, Fudan University, Shanghai, China
2Department of Breast Surgery, Fudan University, Shanghai, China
3Institutes of Biomedical Sciences, Fudan University, Shanghai, China
4Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
Find articles by Hu, X. in: JCI | PubMed | Google Scholar
1Cancer Institute, Fudan University, Shanghai, China
2Department of Breast Surgery, Fudan University, Shanghai, China
3Institutes of Biomedical Sciences, Fudan University, Shanghai, China
4Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
Find articles by Shao, Z. in: JCI | PubMed | Google Scholar
1Cancer Institute, Fudan University, Shanghai, China
2Department of Breast Surgery, Fudan University, Shanghai, China
3Institutes of Biomedical Sciences, Fudan University, Shanghai, China
4Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
Find articles by Zhang, F. in: JCI | PubMed | Google Scholar
1Cancer Institute, Fudan University, Shanghai, China
2Department of Breast Surgery, Fudan University, Shanghai, China
3Institutes of Biomedical Sciences, Fudan University, Shanghai, China
4Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
Find articles by Jin, X. in: JCI | PubMed | Google Scholar
1Cancer Institute, Fudan University, Shanghai, China
2Department of Breast Surgery, Fudan University, Shanghai, China
3Institutes of Biomedical Sciences, Fudan University, Shanghai, China
4Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
Find articles by Cao, A. in: JCI | PubMed | Google Scholar
1Cancer Institute, Fudan University, Shanghai, China
2Department of Breast Surgery, Fudan University, Shanghai, China
3Institutes of Biomedical Sciences, Fudan University, Shanghai, China
4Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
Find articles by
Li, D.
in:
JCI
|
PubMed
|
Google Scholar
|
Published April 29, 2025 - More info
Hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer (HR+/HER2− BC) is the most common subtype, with high risk of long-term recurrence and metastasis. Endocrine therapy (ET) combined with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors is a standard treatment for advanced/metastatic HR+/HER2- BC, but resistance remains a major clinical challenge. We report that kinesin family member C2 (KIFC2) was amplified in approximately 50% HR+/HER2- BC, and its high expression was associated with poor disease outcome, increased tumor protein p53 (TP53) somatic mutation, and active pyrimidine metabolism. Function assays revealed that depletion of KIFC2 suppressed growth and enhanced sensitivity of HR+/HER2- BC cells to tamoxifen and CDK4/6 inhibitors. Mechanistically, KIFC2 stabilized CDK4 by enhancing its interaction with ubiquitin specific peptidase 9 X-linked (USP9X). Importantly, re-expression of CDK4 in KIFC2-depleted cells partially rescued the decreased growth and increased sensitivity to tamoxifen and CDK4/6 inhibitors caused by KIFC2 depletion. Clinically, high KIFC2 mRNA expression was negatively associated with survival rate of HR+/HER2- BC patients received adjuvant ET alone or in combination with CDK4/6 inhibitors. Collectively, these findings identify an important role for KIFC2 in HR+/HER2- BC growth and therapeutic resistance, and support its potential as a therapeutic target and predictive biomarker.